A Double Blind, Double Dummy, Randomised, Multicentre, Two Arm Parallel Group Study to Assess the Efficacy and Safety of FLUTIFORM® pMDI (2 Puffs Bid) vs Seretide® pMDI (2 Puffs Bid) in Subjects Aged ≥12 Years With Moderate to Severe Persistent, Reversible Asthma

Next Previous
Trial Profile

A Double Blind, Double Dummy, Randomised, Multicentre, Two Arm Parallel Group Study to Assess the Efficacy and Safety of FLUTIFORM® pMDI (2 Puffs Bid) vs Seretide® pMDI (2 Puffs Bid) in Subjects Aged ≥12 Years With Moderate to Severe Persistent, Reversible Asthma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Mundipharma (China) Pharmaceutical

    • Most Recent Events

    • 06 Sep 2017 Status changed from planning to recruiting, according to a Vectura media release
    • 21 Mar 2017 According to a Vectura media release, this study is planned to initiate in H2 2017.
    • 02 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top